PharmaMar appoints new director of clinical oncology
Madrid (ots) - PharmaMar, the anti-cancer drug subsidiary of the Zeltia group, announced today that it will strengthen its Research and Clinical Development department with the appointment of Dr Miguel Ángel Izquierdo Delso as new director of Clinical Oncology.
Dr Miguel Ángel Izquierdo Delso, who specialises in medical oncology and is also a practising physician at the Free University of Amsterdam, will take up his new position as PharmaMar's director of Clinical Oncology on 1 of October 2002. Over the last seven years Dr Izquierdo has worked as a key member of the Medical Oncology Service coordinating the New Drug Development Programme of the Catalan Institute of Oncology (ICO), Barcelona, Spain. He began his professional career at the Free University Hospital of Amsterdam, and at the Institute for Drug Development, Cancer Therapy and Research Center San Antonio, Texas, USA, focussing his research on the pre-clinical and clinical development of new anti-tumour drugs.
PharmaMar is dedicated to the discovery and development of marine-derived anti-tumour compounds. PharmaMar HQ are located in Madrid, Spain, with a subsidiary company, PharmaMar USA, in Cambridge, Massachusetts, and PharmaMar AG in Basel, Switzerland. PharmaMar is an operating unit of the Zeltia Group, which is traded on the Spanish stock exchange, and is part of the Ibex-35 stock market index. PharmaMar can be found on the Web at http://www.pharmamar.com
Contact:
Maren Koban
Medical Knowledge Group
Tel: + 44 - 020 7973 4497